Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 32Myelodysplastic Syndromes 25Recurrence 18Multiple Myeloma 17Lymphoma, Non-Hodgkin 14Lymphoma, B-Cell 14Lymphoma 14Leukemia, Lymphocytic, Chronic, B-Cell 13Ovarian Neoplasms 12Hematologic Neoplasms 12Pancreatic Neoplasms 10Melanoma 10Leukemia 9Hodgkin Disease 9Burkitt Lymphoma 9Stomach Neoplasms 8Myeloproliferative Disorders 8Lymphoma, Large B-Cell, Diffuse 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Neoplasms 7Leukemia, Biphenotypic, Acute 7Colorectal Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasm Metastasis 6Lymphoma, Mantle-Cell 6Lymphoma, Follicular 6Leukemia, Myelomonocytic, Juvenile 6Leukemia, Myelomonocytic, Chronic 6Breast Neoplasms 6

Interventions

Cisplatin 15Gemcitabine 14durvalumab 9pembrolizumab 7Oxaliplatin 6Bevacizumab 6Capecitabine 5lenvatinib 4S 1 (combination) 3Liquid Biopsy 3Irinotecan 3Folfox protocol 3Fluorouracil 3Carboplatin 3zanidatamab 2tremelimumab 2envafolimab 2Trastuzumab 2Nivolumab 2Leucovorin 2Injections 2Blood Specimen Collection 2Albumin-Bound Paclitaxel 2trastuzumab deruxtecan 1toripalimab 1tislelizumab 1poly ICLC 1niraparib 1neratinib 1larotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × fludarabine × 90 days × Clear all
NCT07614061 2026-05-29

Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer

Shanghai Zhongshan Hospital

Phase 1 Recruiting
18 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡